中國生物製藥(01177.HK)抗凝血藥物"硫酸氫氯吡格雷片"獲批上市
格隆匯 7 月 2日丨中國生物製藥(01177.HK)宣佈,集團開發的抗凝血藥物"硫酸氫氯吡格雷片"(商品名稱:優立維)已獲得中國國家藥品監督管理局頒發藥品註冊批件,且視同通過仿製藥質量和療效一致性評價。該產品適用於預防動脈粥樣硬化性疾病,包括心肌梗死、缺血性卒中等,已被納入國家基本藥物目錄。該產品獲批上市,將進一步豐富集團在心腦血管領域的產品組合、鞏固集團在該領域的優勢地位。
氯吡格雷是預防凝血的里程碑式藥物,通過作用於血小板表面二磷酸腺苷(ADP)受體,抑制ADP受體依賴性的血小板糖蛋白IIb/IIIa複合物的形成來抑制血小板的聚集,防止發生凝血,進而阻止病理性血栓形成。氯吡格雷抗血小板作用強,安全性高,獲得國內外指南高度認可,是治療腦卒中、心肌梗死及其他外周動脈疾病的一線用藥。優立維的上市,將惠及更多心腦血管疾病患者。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.